» Articles » PMID: 17317730

Significance of Pulmonary Arterial Pressure and Diffusion Capacity of the Lung As Prognosticator in Patients with Idiopathic Pulmonary Fibrosis

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2007 Feb 24
PMID 17317730
Citations 116
Authors
Affiliations
Soon will be listed here.
Abstract

Study Objectives: To evaluate the long-term clinical course of patients with idiopathic pulmonary fibrosis (IPF) complicated with pulmonary arterial hypertension.

Design: Prospective analysis of consecutive IPF patients undergoing initial workup with right-heart catheterization (RHC) and pulmonary function testing (PFT). Pulmonary arterial pressure (PAP) and diffusion capacity of the lung for carbon monoxide (Dlco) were focused on.

Setting: University hospital.

Patients: Seventy-eight patients with IPF (67 men, 11 women; diagnosis by pathology, n = 59; clinical diagnosis, n = 19) had been followed up after initial workup for a maximum of 14 years.

Measurements And Results: RHC data on 61 patients and PFT data on 52 patients were available. Five-year survival rates were 62.2% in the normal-PAP group (mean PAP < 17 mm Hg, n = 37) and 16.7% in the high-PAP group (mean PAP > 17 mm Hg, n = 24) [p < 0.001]; 70.4% in the preserved-Dlco group (percentage of predicted > 40%, n = 27) and 20.0% in the low-Dlco group (percentage of predicted < 40%, n = 25) [p < 0.001]; and 82.6% in group 1 (normal PAP and preserved Dlco, n = 23) and 15.6% in group 2 (high PAP, low Dlco, or both, n = 32) [p < 0.0001]. The relative risks of mortality within 5 years after RHC were 2.20 (95% confidence interval [CI], 1.40 to 3.45) in the high-PAP group, 2.70 (95% CI, 1.46 to 4.99) in the low-Dlco group, and 4.85 (95% CI, 1.97 to 11.97) in group 2.

Conclusion: Dlco was a critical factor for evaluating disease status and prognosis, and PAP status provided feasible information in the initial workup of IPF patients.

Citing Articles

Analysis of clinical features and risk factors of pulmonary hypertension associated with interstitial lung disease.

Liao Y, Wu B Biomed Rep. 2025; 22(4):58.

PMID: 39991007 PMC: 11843187. DOI: 10.3892/br.2025.1936.


Systematic evaluation of subgroup analyses of inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.

Martinez-Puig P, Baez-Gutierrez N, Rodriguez-Ramallo H, Abdelkader-Martin L, Otero-Candelera R PLoS One. 2025; 20(2):e0318739.

PMID: 39937727 PMC: 11819518. DOI: 10.1371/journal.pone.0318739.


Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative-group 3 pulmonary hypertension.

Vitulo P, Piccari L, Wort S, Shlobin O, Kovacs G, Vizza C Pulm Circ. 2024; 14(4):e70005.

PMID: 39659477 PMC: 11629413. DOI: 10.1002/pul2.70005.


Diagnosis and Management of Pulmonary Hypertension: New Insights.

Ntiloudi D, Kasinos N, Kalesi A, Vagenakis G, Theodosis-Georgilas A, Rammos S Diagnostics (Basel). 2024; 14(18).

PMID: 39335731 PMC: 11431164. DOI: 10.3390/diagnostics14182052.


Burden of illness in patients with pulmonary hypertension due to interstitial lung disease: a real-world analysis.

Heresi G, Dean B, Wu B, Lee H, Sketch M, Stafkey-Mailey D BMC Pulm Med. 2024; 24(1):335.

PMID: 38992626 PMC: 11242015. DOI: 10.1186/s12890-024-03141-3.